Galaxy Biomedical Investment Co., Ltd. announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced sales was CNY 189.042 million compared to CNY 160.729 million a year ago. Operating loss was CNY 6.987 million compared to CNY 11.907 million a year ago. Net loss was CNY 8.381 million compared to CNY 12.415 million a year ago. Basic loss per share from continuing operations was CNY 0.0076 compared to CNY 0.0113 a year ago.